id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-026493-z2hthkgy	Newsom, Megan	New and Emerging Systemic Treatments for Atopic Dermatitis	2020-06-09		.txt	text/plain	4136	198	47	In two phase III clinical trials, BREEZE-AD1 and BREEZE-AD2, by 16 weeks, a higher proportion of subjects in the treatment groups (1 mg, 2 mg, and 4 mg) achieved an IGA of 0 or 1, a ≥ 2-point improvement, and EASI-75 compared with the group receiving placebo (Table 1 ) [40] . In a phase IIb trial evaluating abrocitinib in moderate-to-severe AD by week 12, a higher proportion of subjects receiving 200 mg of drug and 100 mg of drug (43.8% and 29.6%) had an IGA of 0 or 1 plus a ≥ 2-point improvement from baseline compared with those receiving placebo (5.8%; p < 0.001 and p < 0.001, respectively) [41] . Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 Randomized Clinical Trial Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b Randomized Clinical Trial	./cache/cord-026493-z2hthkgy.txt	./txt/cord-026493-z2hthkgy.txt